Gregory Dean A., a director at Cerus Corp (NASDAQ:CERS), recently acquired additional shares of the company’s common stock. According to a recent SEC filing, Dean purchased 1,725 shares at a price of $1.70 per share, totaling an investment of $2,932. The purchase comes as the stock trades near its InvestingPro Fair Value, with the company showing strong revenue growth of ~15% in the last twelve months. This transaction increases his total holdings to 61,725 shares, reflecting his ongoing commitment to the company. While the stock has declined ~27% over the past year, Cerus maintains a healthy balance sheet with a current ratio of 2.59. InvestingPro subscribers can access detailed insider trading analysis and comprehensive financial health metrics in the Pro Research Report, available for over 1,400 US stocks.
In other recent news, Cerus Corporation reported a significant Q3 revenue growth of 16%, amounting to $46 million, mainly driven by its North American platelet business. The company also revised its full-year product revenue guidance upwards, influenced by positive trends in its INTERCEPT Fibrinogen Complex (IFC) business and increased production capacity. Furthermore, Cerus secured a $248 million contract with BARDA to advance the INTERCEPT Red Blood Cell program, addressing public health concerns related to blood supply safety.
In addition, Cerus Corporation recently announced the extension of their supply and manufacturing agreement with Porex Corporation, termed the "2025 Agreement." This contract extension aims to ensure the continued supply of key components for Cerus’s products, a strategic move for the company’s supply chain stability. The specifics of the pricing and the financial terms were not disclosed in the announcement.
In the same vein, Cerus Corporation plans to launch an LED illuminator in Europe in 2025 and in the U.S. in 2026. Growth is anticipated from new customer acquisitions and increased usage among existing clients. These are among the recent developments for Cerus Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.